75 related articles for article (PubMed ID: 24366194)
1. HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.
Nielsen TO; Poulsen SS; Journe F; Ghanem G; Sorensen BS
Melanoma Res; 2014 Feb; 24(1):88-91. PubMed ID: 24366194
[TBL] [Abstract][Full Text] [Related]
2. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
[TBL] [Abstract][Full Text] [Related]
4. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
5. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM; Shrieve DC; Zempolich KA; Lee RJ; Hammond E; Handrahan DL; Gaffney DK
Gynecol Oncol; 2005 Nov; 99(2):415-21. PubMed ID: 16157365
[TBL] [Abstract][Full Text] [Related]
6. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
Boone B; Brochez L
Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
[TBL] [Abstract][Full Text] [Related]
7. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
8. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
10. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract][Full Text] [Related]
11. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
12. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
13. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma.
Fuchs I; Vorsteher N; Bühler H; Evers K; Sehouli J; Schaller G; Kümmel S
Anticancer Res; 2007; 27(2):959-63. PubMed ID: 17465227
[TBL] [Abstract][Full Text] [Related]
17. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
18. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
19. EGFR in melanoma: clinical significance and potential therapeutic target.
Boone B; Jacobs K; Ferdinande L; Taildeman J; Lambert J; Peeters M; Bracke M; Pauwels P; Brochez L
J Cutan Pathol; 2011 Jun; 38(6):492-502. PubMed ID: 21352258
[TBL] [Abstract][Full Text] [Related]
20. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]